Medtronic receives fda breakthrough designation for the emprint™ ablation catheter kit

Minimally invasive option has potential to provide long-term management of lung malignancies while protecting lung function dublin, april 27, 2021 /prnewswire/ -- medtronic plc (nyse:mdt), the global leader in medical technology, today announced it has received breakthrough device designation status from the u.s. food and drug administration (fda) for the emprint™ ablation catheter kit – an investigational device not yet approved or cleared in the united states. the catheter is intended to be used in conjunction with the emprint™ microwave generator and medtronic lung navigation platform to provide a minimally invasive, localized treatment of malignant lesions in the lung, and it can be used together with standard of care therapy when indicated.
MDT Ratings Summary
MDT Quant Ranking